C-Peptide Test: When to Order It and What Your Results Mean

What Is C-Peptide and Why Does It Matter for Women?

C-peptide (connecting peptide) is produced in a 1:1 molar ratio with insulin every time a pancreatic beta cell splits proinsulin into its active components. Because C-peptide is not extracted by the liver on its first pass the way insulin is, its blood level is a cleaner, more stable reflection of how hard your pancreas is actually working. Measuring C-peptide gives your clinician information that a standard fasting glucose or even a hemoglobin A1c cannot: it tells you why your blood sugar is behaving the way it is.

For women specifically, this distinction matters across multiple life stages. Insulin resistance is woven into conditions that disproportionately affect women: PCOS affects an estimated 6 to 12 percent of reproductive-age women in the US, and the metabolic component of PCOS is driven largely by hyperinsulinemia. Gestational diabetes mellitus (GDM) complicates roughly 6 to 9 percent of all pregnancies. The menopause transition brings a documented shift in fat distribution and insulin sensitivity that is independent of aging itself.

C-peptide sits at the intersection of all of these.

C-Peptide vs. Insulin: Which Test Do You Actually Need?

Both C-peptide and fasting insulin measure pancreatic output, but they are not interchangeable. Exogenous insulin (injected or infused) does not contain C-peptide, so if a patient is already on insulin therapy, a C-peptide test still accurately reflects endogenous pancreatic production while a serum insulin test would be falsely elevated. The Endocrine Society recommends C-peptide over serum insulin when you need to determine residual beta-cell function in a person already using insulin.

Fasting insulin is cheaper and more widely available, and it is a reasonable first-line screen for insulin resistance in women who are not yet on insulin therapy. If the result is ambiguous or if the clinical question is about beta-cell reserve (for example, distinguishing latent autoimmune diabetes in adults, LADA, from type 2 diabetes), C-peptide is the more informative test.

How the Test Works

You fast for at least eight hours. A single venous blood draw is taken, ideally before 9 a.m. To minimize cortisol interference. Some clinicians also order a stimulated C-peptide, drawn 90 minutes after a mixed meal or a glucagon injection, when fasting values are borderline and a more complete picture of beta-cell capacity is needed. The stimulated C-peptide threshold of 0.2 nmol/L is used in research and clinical practice to define clinically significant residual beta-cell function in people with established diabetes.

Normal C-Peptide Range: What the Numbers Mean

A fasting C-peptide between 0.8 and 3.1 ng/mL (approximately 0.26 to 1.03 nmol/L) is generally considered within the reference range in non-pregnant adults, based on laboratory reference intervals reported by major academic medical centers. Different assays use different units; always check the reference range on your own lab report because analyzers vary.

High C-Peptide: Too Much Pancreatic Output

A fasting C-peptide above 3.1 ng/mL signals that the pancreas is working overtime. The most common reason in women of reproductive age is insulin resistance: the body's cells are not responding to insulin properly, so the pancreas compensates by making more. Conditions to consider include:

• PCOS with hyperinsulinemia
• Obesity or visceral adiposity, including metabolic syndrome
• Prediabetes or early type 2 diabetes, before the pancreas has begun to fail
• Cushing syndrome, where excess cortisol drives insulin resistance
• Insulinoma (rare), a pancreatic tumor that autonomously secretes insulin and C-peptide together; insulinoma is slightly more common in women than in men

In perimenopause, estrogen withdrawal reduces insulin sensitivity in skeletal muscle and adipose tissue. A 2020 analysis published in Menopause found that insulin resistance increases significantly during the menopause transition, independent of body weight change, which means C-peptide can begin rising even when your scale has not moved.

Low C-Peptide: Beta-Cell Failure or Suppression

A fasting C-peptide below 0.8 ng/mL, especially in the presence of hyperglycemia, points toward inadequate beta-cell function. Common scenarios include:

• Type 1 diabetes (T1D): autoimmune destruction of beta cells leaves little or no C-peptide
• LADA (latent autoimmune diabetes in adults): slower autoimmune process, often misdiagnosed as type 2; C-peptide declines over months to years
• Long-standing type 2 diabetes with beta-cell exhaustion
• Factitious hypoglycemia from exogenous insulin: low blood glucose plus low C-peptide (because the injected insulin suppresses the pancreas) is the classic forensic pattern

The American Diabetes Association Standards of Care note that a C-peptide level <0.6 ng/mL (0.2 nmol/L) in the setting of diabetes is consistent with absolute insulin deficiency, supporting a T1D or insulin-requiring classification regardless of age at diagnosis.

When Should You Order a C-Peptide Test? A Clinician's Decision Framework

The following framework reflects how WomanRx clinicians approach the C-peptide order decision across a woman's life stages. It is not a replacement for individualized clinical judgment.

Scenario 1: You Have a New Diabetes Diagnosis and the Type Is Unclear

This is the most evidence-backed indication. Women diagnosed with diabetes after age 30, especially women with a higher BMI, are frequently assumed to have type 2 diabetes. But up to 10 percent of adults initially labeled with type 2 diabetes actually have LADA, and LADA is more common in women than in men in some population studies. A C-peptide that is low at diagnosis, or that declines rapidly over one to two years, combined with positive islet autoantibodies (anti-GAD65, IA-2), confirms LADA and changes treatment: these women need insulin far sooner than a standard type 2 protocol would suggest.

Order C-peptide (with anti-GAD65 antibody) if:

• Diagnosis is in an adult who does not fit the typical type 2 profile
• Response to oral agents is poor within six to twelve months
• A personal or family history of other autoimmune conditions exists (thyroid disease, celiac, rheumatoid arthritis)

Scenario 2: PCOS Workup or Suspected Hyperinsulinemia

PCOS guidelines from ACOG (Practice Bulletin 194) and the 2023 International Evidence-Based Guideline for PCOS both recommend assessing metabolic risk in every woman with PCOS at diagnosis. A fasting insulin is usually ordered first because it is cheaper, but C-peptide adds value when:

• Fasting insulin is borderline and you want a second, more stable measure
• The patient is already on metformin (which does not affect C-peptide but can lower circulating insulin)
• You want to track beta-cell load over time as a treatment response marker

A high C-peptide in a woman with PCOS confirms that her hyperandrogenism is driven substantially by hyperinsulinemia, which has direct management implications: insulin-lowering strategies (metformin, inositol, low-glycemic diet, weight loss where applicable) become first-line priorities alongside standard PCOS care.

Scenario 3: Perimenopause and Unexplained Metabolic Shift

Women in perimenopause often notice weight gain concentrated at the abdomen, worsening fasting glucose, and higher A1c despite no change in diet or exercise. A longitudinal study from the Study of Women's Health Across the Nation (SWAN) showed that insulin resistance increased significantly during the menopause transition, with the sharpest rise in the two years surrounding the final menstrual period. C-peptide ordered in this context documents the degree of compensatory hyperinsulinemia and helps justify intensive lifestyle or pharmacologic intervention before glucose meets the diagnostic threshold for diabetes.

Order C-peptide in perimenopause when:

• Fasting glucose is 95 to 125 mg/dL (below the diabetes cutoff but trending up)
• A1c is rising without a clear dietary cause
• The patient has a family history of type 2 diabetes and is approaching or past 45 years of age

Scenario 4: Unexplained Hypoglycemia

Recurrent low blood sugar in a woman who is not on insulin or a sulfonylurea requires a systematic workup. The critical C-peptide cutoff during a documented hypoglycemic episode (blood glucose <55 mg/dL) is 0.6 ng/mL:

• C-peptide high during hypoglycemia: insulinoma, nesidioblastosis, sulfonylurea ingestion (accidental or intentional)
• C-peptide low during hypoglycemia: exogenous insulin administration (factitious hypoglycemia), non-islet-cell tumor hypoglycemia, adrenal insufficiency

The Endocrine Society Clinical Practice Guideline on Hypoglycemia specifies that a 72-hour fast with serial glucose, insulin, C-peptide, and proinsulin sampling is the reference-standard test for suspected insulinoma. Insulinoma has a female predominance of approximately 60 percent.

C-Peptide in Pregnancy and Gestational Diabetes

Pregnancy changes everything about pancreatic physiology. Placental hormones, particularly human placental lactogen and progesterone, progressively reduce insulin sensitivity across the second and third trimester. To compensate, a healthy pregnancy involves a physiologic two- to threefold increase in beta-cell mass and insulin secretion. C-peptide rises throughout pregnancy, so a value of 3.5 or even 4 ng/mL in the third trimester may be entirely normal.

What C-Peptide Tells You in GDM

In women who develop gestational diabetes mellitus, C-peptide can clarify which underlying mechanism is dominant: inadequate beta-cell response (more common in women with lean GDM or those who have pre-existing beta-cell compromise) versus severe insulin resistance with an initially adequate beta-cell response that eventually fails. This distinction is not yet part of routine GDM management per ACOG Practice Bulletin 190, but it has prognostic value: women with lower C-peptide during GDM have a higher risk of progressing to type 2 or type 1 diabetes postpartum.

C-Peptide in Pre-existing T1D During Pregnancy

For women with T1D who are pregnant or trying to conceive, a measurable C-peptide (even above 0.2 ng/mL) is associated with better glycemic control during pregnancy and a lower rate of severe hypoglycemia, based on data from the CONCEPTT trial, which enrolled 322 pregnant women with T1D. Preserved residual beta-cell function, however small, buffers against nocturnal hypoglycemia, which is a particular risk in the first trimester.

Postpartum Considerations

Women with GDM should have a 75 g oral glucose tolerance test (OGTT) at 4 to 12 weeks postpartum per ACOG guidelines. Adding a fasting C-peptide to that postpartum OGTT is not yet standard, but some endocrinologists use it to identify women whose beta-cell reserve is already reduced, flagging them for earlier type 2 diabetes prevention interventions. The evidence for this practice is observational; a definitive trial has not been conducted.

How to Lower a High C-Peptide

If your C-peptide is high, the goal is to reduce the insulin demand your body is placing on the pancreas. This means improving insulin sensitivity.

Dietary Approaches

A low-glycemic or lower-carbohydrate diet reduces postprandial glucose spikes and, over time, lowers fasting insulin and C-peptide. A 2021 meta-analysis in Diabetes Care found that low-carbohydrate diets (defined as <130 g carbohydrate per day) produced significantly greater reductions in fasting insulin compared with low-fat control diets at six months. Caloric restriction independent of macronutrient composition also lowers C-peptide by reducing visceral adiposity.

Exercise

Resistance training and aerobic exercise both improve skeletal muscle insulin sensitivity, the primary site of glucose disposal. A 12-week structured exercise program in women with PCOS lowered fasting insulin by a mean of 3.2 µIU/mL in a 2020 RCT published in the Journal of Clinical Endocrinology and Metabolism, with corresponding reductions in testosterone, suggesting the metabolic and androgenic components of PCOS are tightly linked through insulin.

Medications

• Metformin is first-line for insulin resistance in PCOS and prediabetes in women. It lowers hepatic glucose production and reduces fasting C-peptide over six to twelve months of use.
• GLP-1 receptor agonists (semaglutide, liraglutide) reduce C-peptide indirectly by improving insulin sensitivity and promoting weight loss. The SCALE Obesity trial showed that liraglutide 3.0 mg reduced fasting insulin significantly versus placebo at 56 weeks, with a mean bodyweight reduction of 8.4 kg.
• Inositol (myo-inositol and D-chiro-inositol) is used off-label in PCOS to improve insulin signaling. Evidence is promising but comes largely from small trials; a 2019 Cochrane review concluded that inositol may improve hormonal and metabolic parameters in PCOS but that evidence quality is moderate.

How to Raise a Low C-Peptide

Low C-peptide from autoimmune beta-cell destruction cannot be reversed by lifestyle alone, and no approved therapy currently restores significant beta-cell mass in adults with established T1D. The focus shifts to protecting whatever residual function remains.

Preserve Residual Beta-Cell Function in T1D

Tight glycemic control slows the rate of residual beta-cell loss. The DCCT trial demonstrated that intensive insulin therapy preserved C-peptide detectability for longer than conventional therapy in newly diagnosed T1D, and preserved C-peptide was associated with lower rates of retinopathy and hypoglycemia.

Teplizumab (Tzield), an anti-CD3 monoclonal antibody, received FDA approval in November 2022 and delays the onset of clinical T1D by a median of approximately two years in high-risk individuals (stage 2 T1D, meaning two or more autoantibodies plus dysglycemia). It does not raise C-peptide in established T1D but may preserve baseline levels if started before overt disease. Teplizumab is not approved in pregnancy; reliable contraception is required during treatment given the absence of human gestational safety data.

Pancreatic Enzyme Replacement and Exocrine Pancreatic Insufficiency

Chronic pancreatitis can destroy both exocrine and endocrine tissue. In women with a history of gallstone pancreatitis (which is more common in women than men, particularly after pregnancy), a low C-peptide may reflect Type 3c (pancreatogenic) diabetes. Treatment is insulin, not oral agents, and the dose requirement is often lower than in T1D because glucagon secretion is also impaired, increasing hypoglycemia risk.

Who This Test Is Right For (and Who It Is Not)

Order C-Peptide If You Are:

• A woman with a new or uncertain diabetes diagnosis, especially if you have other autoimmune conditions
• Managing PCOS with suspected hyperinsulinemia and fasting insulin is borderline
• In perimenopause with a rising A1c or fasting glucose between 95 and 125 mg/dL
• Experiencing recurrent unexplained hypoglycemia and not on insulin or a sulfonylurea
• Pregnant with pre-existing T1D and your endocrinologist needs to assess residual beta-cell function

C-Peptide Is Less Useful If You Are:

• Already well-established in type 2 diabetes management with a clear clinical picture; A1c and fasting glucose are sufficient for monitoring
• Seeking a general metabolic screen when you have no symptoms; a fasting lipid panel and fasting glucose are better first steps
• Using C-peptide to diagnose insulin resistance on its own; a high-normal C-peptide in isolation is not diagnostic

Evidence Gaps: What We Still Do Not Know in Women

Women have been under-represented in the major beta-cell biology trials. The DCCT enrolled roughly equal numbers of men and women, which is relatively unusual. Most insulinoma case series are too small to draw sex-stratified conclusions about C-peptide thresholds with confidence. Reference ranges for C-peptide have not been fully validated across the menstrual cycle, though one small study suggested C-peptide may be marginally higher in the luteal phase due to progesterone-driven insulin resistance. No large trial has established trimester-specific C-peptide reference ranges for pregnant women, meaning clinicians currently interpret pregnancy values against non-pregnant norms, which is imprecise.

As WomanRx reviewer Maya Okafor, MD, notes: "The single most common clinical error I see with C-peptide is interpreting a result from a pregnant woman using the standard non-pregnant reference range. A value of 3.5 ng/mL in the third trimester is almost certainly physiologic, not a sign of insulin resistance, but it will flag as high on a standard lab report and can trigger unnecessary workup if the clinician does not account for the gestational shift in beta-cell output."

Practical Steps Before You Order

1. Confirm a minimum eight-hour fast. A post-meal C-peptide can run two to three times higher than fasting and will not be interpretable against standard reference ranges without a stimulation protocol.
2. Note all medications on the requisition. Sulfonylureas and meglitinides stimulate insulin secretion and will raise C-peptide; corticosteroids will raise it through insulin resistance; exogenous insulin will not change it.
3. Check kidney function. C-peptide is cleared partly by the kidneys. An eGFR below 30 mL/min/1.73 m² elevates C-peptide independently of pancreatic function and can produce falsely high results.
4. Pair with fasting glucose and, where indicated, anti-GAD65 and IA-2 antibodies. C-peptide in isolation answers fewer questions than C-peptide in clinical context.